185 related articles for article (PubMed ID: 31880161)
1. Risk factors differentially associated with non-alcoholic fatty liver disease in males and females with metabolic syndrome.
Bullón Vela MV; Abete I; Zulet MLÁ; Tur JA; Pintó X; Corbella E; Martínez González MÁ; Corella D; Macías González M; Tinahones F; Fitó M; Estruch R; Ros E; Salas Salvadó J; Daimiel L; Martínez JA
Rev Esp Enferm Dig; 2020 Feb; 112(2):94-100. PubMed ID: 31880161
[TBL] [Abstract][Full Text] [Related]
2. Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features.
Bullón-Vela V; Abete I; Tur JA; Pintó X; Corbella E; Martínez-González MA; Toledo E; Corella D; Macías M; Tinahones F; Fitó M; Estruch R; Ros E; Salas-Salvadó J; Daimiel L; Zulet MA; Martínez JA;
Nutrition; 2020 Mar; 71():110620. PubMed ID: 31838461
[TBL] [Abstract][Full Text] [Related]
3. Visceral and subcutaneous abdominal fat is associated with non-alcoholic fatty liver disease while augmenting Metabolic Syndrome's effect on non-alcoholic fatty liver disease: A cross-sectional study of NHANES 2017-2018.
Elguezabal Rodelo RG; Porchia LM; Torres-Rasgado E; López-Bayghen E; Gonzalez-Mejia ME
PLoS One; 2024; 19(2):e0298662. PubMed ID: 38394065
[TBL] [Abstract][Full Text] [Related]
4. Role of NAFLD on the Health Related QoL Response to Lifestyle in Patients With Metabolic Syndrome: The PREDIMED Plus Cohort.
Martínez-Urbistondo D; San Cristóbal R; Villares P; Martínez-González MÁ; Babio N; Corella D; Del Val JL; Ordovás JM; Alonso-Gómez ÁM; Wärnberg J; Vioque J; Romaguera D; López-Miranda J; Estruch R; Tinahones FJ; Lapetra J; Serra-Majem JL; Bueno-Cavanillas A; Tur JA; Marcos A; Pintó X; Delgado-Rodríguez M; Matía-Martín P; Vidal J; Vázquez C; Ros E; Bullón Vela MV; Palau A; Masagué M; Abete I; Moreno-Rodríguez A; Candela-García I; Konieczna J; García-Ríos A; Juárez OL; Martín P; Goday A; Zulet MÁ; Vaquero-Luna J; Orea MDCS; Megías I; Baltasar E; Martínez JA; Daimiel L
Front Endocrinol (Lausanne); 2022; 13():868795. PubMed ID: 35846291
[TBL] [Abstract][Full Text] [Related]
5. Association between Non-Alcoholic Fatty Liver Disease and Mediterranean Lifestyle: A Systematic Review.
Mascaró CM; Bouzas C; Tur JA
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010923
[TBL] [Abstract][Full Text] [Related]
6. Association between Mediterranean Diet and Fatty Liver in Women with Overweight and Obesity.
Leone A; Bertoli S; Bedogni G; Vignati L; Pellizzari M; Battezzati A
Nutrients; 2022 Sep; 14(18):. PubMed ID: 36145146
[TBL] [Abstract][Full Text] [Related]
7. Gender differences in the association of non-alcoholic fatty liver disease and metabolic syndrome with erosive oesophagitis: a cross-sectional study in a Taiwanese population.
Hung WC; Wu JS; Sun ZJ; Lu FH; Yang YC; Chang CJ
BMJ Open; 2016 Nov; 6(11):e013106. PubMed ID: 27852719
[TBL] [Abstract][Full Text] [Related]
8. Correlation between non-alcoholic fatty liver with metabolic risk factors and brachial-ankle pulse wave velocity.
Zhu WH; Fang LZ; Lu CR; Dai HL; Chen JH; Qiao QH; Chen LY
World J Gastroenterol; 2015 Sep; 21(35):10192-9. PubMed ID: 26401084
[TBL] [Abstract][Full Text] [Related]
9. Estimation of fatty liver disease clinical role on glucose metabolic remodelling phenotypes and T2DM onset.
Martinez-Urbistondo D; Huerta A; Navarro-González D; Sánchez-Iñigo L; Fernandez-Montero A; Landecho MF; Martinez JA; Pastrana-Delgado JC
Eur J Clin Invest; 2023 Oct; 53(10):e14036. PubMed ID: 37303077
[TBL] [Abstract][Full Text] [Related]
10. The newly proposed Metabolic Score for Visceral Fat is a reliable tool for identifying non-alcoholic fatty liver disease, requiring attention to age-specific effects in both sexes.
Kuang M; Qiu J; Li D; Hu C; Zhang S; Sheng G; Zou Y
Front Endocrinol (Lausanne); 2023; 14():1281524. PubMed ID: 38089634
[TBL] [Abstract][Full Text] [Related]
11. The association between healthy eating index-2015 with anthropometric, cardiometabolic and hepatic indices among patients with non-alcoholic fatty liver disease.
Hosseini SA; Shayesteh AA; Hashemi SJ; Rahimi Z; Saki N; Bavi Behbahani H; Cheraghian B; Alipour M
BMC Gastroenterol; 2024 May; 24(1):159. PubMed ID: 38724894
[TBL] [Abstract][Full Text] [Related]
12. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
[TBL] [Abstract][Full Text] [Related]
13. Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men.
Choi YJ; Lee DH; Han KD; Yoon H; Shin CM; Park YS; Kim N
PLoS One; 2018; 13(9):e0201308. PubMed ID: 30231041
[TBL] [Abstract][Full Text] [Related]
14. Association of Serum Bilirubin With Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Liang C; Yu Z; Bai L; Hou W; Tang S; Zhang W; Chen X; Hu Z; Duan Z; Zheng S
Front Endocrinol (Lausanne); 2022; 13():869579. PubMed ID: 35937795
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol efflux capacity is impaired in subjects with an elevated Fatty Liver Index, a proxy of non-alcoholic fatty liver disease.
van den Berg EH; Gruppen EG; Ebtehaj S; Bakker SJL; Tietge UJF; Dullaart RPF
Atherosclerosis; 2018 Oct; 277():21-27. PubMed ID: 30170220
[TBL] [Abstract][Full Text] [Related]
16. Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach.
Feldman A; Eder SK; Felder TK; Paulweber B; Zandanell S; Stechemesser L; Schranz M; Strebinger G; Huber-Schönauer U; Niederseer D; Patsch W; Weghuber D; Tevini J; Datz C; Aigner E
Diabetes Metab; 2019 Apr; 45(2):132-139. PubMed ID: 30266576
[TBL] [Abstract][Full Text] [Related]
17. Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance.
Yang KC; Hung HF; Lu CW; Chang HH; Lee LT; Huang KC
Sci Rep; 2016 Jun; 6():27034. PubMed ID: 27246655
[TBL] [Abstract][Full Text] [Related]
18. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
Scicali R; Di Pino A; Urbano F; Ferrara V; Marchisello S; Di Mauro S; Scamporrino A; Filippello A; Rabuazzo AM; Purrello F; Piro S
Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):869-879. PubMed ID: 33549441
[TBL] [Abstract][Full Text] [Related]
19. Adherence to Mediterranean Diet and NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study.
Montemayor S; Mascaró CM; Ugarriza L; Casares M; Llompart I; Abete I; Zulet MÁ; Martínez JA; Tur JA; Bouzas C
Nutrients; 2022 Aug; 14(15):. PubMed ID: 35956364
[TBL] [Abstract][Full Text] [Related]
20. The differing influence of several factors on the development of fatty liver with elevation of liver enzymes between genders with metabolic syndrome: A cross-sectional study.
Sogabe M; Okahisa T; Nakasono M; Fukuno H; Miyamoto Y; Okada Y; Okazaki J; Miyoshi J; Tomonari T; Taniguchi T; Goji T; Kitamura S; Miyamoto H; Muguruma N; Takayama T
PLoS One; 2017; 12(6):e0177925. PubMed ID: 28574988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
